MA-ULTIVUE
12.5.2022 16:07:07 CEST | Business Wire | Press release
Ultivue, Inc., an industry leader in multiplexing assays and analytics solutions for tissue biomarker studies, announced today multiple collaborations for AI-powered spatial phenomics solutions for translational research groups and Biopharma.
Ultivue develops unique workflows for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in precious tissue samples. It combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation. Different capabilities are needed depending on the scientific question under investigation, the size of cohorts and the stage of the biomarker development program. Ultivue is complementing its own Image Data Services with capabilities provided by trusted partners to offer end-to-end support for customers. Flexible image analysis solutions as provided by Visiopharm and Indica Labs can effectively be used to provide rich readouts from bespoke mIF assays developed to address a scientific question. These solutions can be used at Ultivue, by the customer or at OracleBio – in GCP-compliant workflows. Co-marketing agreements with Aignostics , Keen Eye , and Nucleai , enable Ultivue to offer AI solutions that optimally complement mIF assays for the efficient analysis of larger cohorts. Hands-on time per image and consistency of readouts can be significantly improved and results can be reviewed in web-based viewers – a viewer optimized for mIF and same-slide H&E has been co-developed with Aignostics . Ultivue is also collaborating with Paige to bring AI-based analytics into clinical workflows and with Zegami leveraging AI to interactively explore image and analysis data from large cohorts for quality control and scientific interpretation.
All these agreements enable Ultivue to present a cohesive workflow to biopharma customers that combines the power of mIF and AI development ensuring a seamless integration of assay coupled to analysis. As noted by Florian Leiss, VP Digital Health Strategies, “Leveraging the full potential of mIF and AI for translational science and in clinical trials will require different capabilities at different stages. We are excited to work with trusted partners to complement mIF assays with image and data analysis across the entire spectrum of tissue biomarker development. We jointly accelerate the journey for our biopharma customers and enable them to focus on the science in a way no single player could alone.”
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005347/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Money20/20 Europe Announces Powerhouse Speaker Lineup Featuring Leaders from Klarna, BBVA, ABN AMRO, Mastercard, eToro, and Revolut19.5.2026 10:10:00 CEST | Press release
Leading voices in payments, banking, and fintech innovation to take the stage in Amsterdam Money20/20, the world’s leading fintech show and the place where money does business, today announced a stellar line-up of speakers for Money20/20 Europe happening on June 2-4 at the RAI in Amsterdam. The show will feature 450+ speakers across six stages, exploring the forces redefining global finance through AI innovation, digital assets, and regulatory transformation. Newly confirmed speakers include some of the most influential voices shaping the future of payments, banking, and financial services: Sebastian Siemiatkowski, Co-Founder and CEO, Klarna. A pioneer in the buy now, pay later revolution, Siemiatkowski has transformed consumer payments and continues to drive innovation in embedded finance and AI-powered shopping experiences. Onur Genç, CEO, BBVA. Leading one of Europe's most digitally advanced banks, Genç is at the forefront of banking transformation, leveraging data, technology, and
Mythic Acquires Videantis, One of Europe’s Leading Digital Processor IP Companies, to Build the World’s Most Energy-Efficient AI Compute Platform19.5.2026 10:00:00 CEST | Press release
Silicon Valley and German engineering unite to create a new AI compute champion for Europe and the world Mythic, a pioneer in analog compute-in-memory and architect of the industry’s most energy-efficient AI acceleration technology, today announced it has acquired Videantis GmbH, one of Europe’s leading digital processor IP companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519255958/en/ The transaction unites Mythic’s breakthrough analog compute platform with Videantis’ highly differentiated, unified digital processor architecture and production-proven software stack — accelerating Mythic’s delivery of a new class of hybrid AI compute platform with a 100x energy efficiency advantage over conventional GPU-based systems. This deal builds on Mythic’s recently announced agreement with Honda to co-develop next-generation AI chips for future vehicles — a validation of Mythic’s game-changing architecture in one of the wo
Splio Enters a New Phase of Its Regional Development in Southern Europe19.5.2026 09:00:00 CEST | Press release
As consumers integrate AI into their everyday web usage, Splio is strengthening its presence in Barcelona to help companies across the region make CRM a central lever in the age of agentic commerce Splio is strengthening its presence in Barcelona, which is set to play the role of a second headquarters, to drive its development across Southern Europe.Splio is reinforcing governance, teams and resources deployed in the region.With its AI-first CRM, Splio aims to help companies from retail to travel strengthen the business contribution of CRM. A few months after launching its AI-first CRM, Splio is entering a new phase of its development in Southern Europe. Already established for more than 12 years in Spain, Portugal and Italy, the company has chosen to invest further in the region, convinced that it combines economic potential with rapidly evolving digital usage. Antoine Parizot, Splio’s co-CEO, is relocating to Barcelona, where the company’s historic office is based. At the same time,
KfW, Germany’s largest national promotional bank, future-proofs regulatory reporting, by migrating to Regnology Reporting Hub (RRH)19.5.2026 08:33:00 CEST | Press release
Longstanding client transitions to the next-generation RRH solution, delivered on Regnology’s Rcloud architecture Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced that KfW Bankengruppe (KfW) is advancing its long-term partnership with the company by electing to migrate to the next-generation Regulatory Reporting Hub (RRH). The solution will be delivered as a cloud-native service on Rcloud, Regnology’s high-performance cloud architecture layer. This strategic move to the modern RRH platform future-proofs the mission-critical reporting functions for one of the world's leading promotional banks. Headquartered in Frankfurt am Main, KfW is a public‑law institution dedicated to supporting sustainable economic, social and ecological development in Germany, across Europe and globally. Regnology’s foresight led to the 2023 launch of Rcloud, its state-of-the-art architecture layer built on Google Cloud, enabling next‑generation so
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth19.5.2026 08:00:00 CEST | Press release
ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513198633/en/ ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth Mark Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the Company’s growth, including the successful closing of its Series A financing, the expansion of the scientific team, and the advancement of its therapeutic programs. In his new role, he will lead ATB’s strategy and senior leadership team as the Company prepares to enter clinical deve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom